Navigation Links
Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Date:5/13/2010

HARBIN, China, May 13 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company successfully exhibited its products at the 63rd PHARMACHINA fair("The Fair") held in Xiamen, China.

The PHARMACHINA Fair brought a diverse audience of consumers, distributors, and media to Renhuang's booth to learn more about the Company's innovative all-natural plant-based products. The Company showcased its series products based on Siberian Ginseng (Acanthopanax), which has well-documented benefits for treating depression and anxiety without the side effect often associated with chemical-based drugs. Based on participation at the Fair, Renhuang has secured several new business opportunities which the Company believes will contribute approximately $3.0 million to its fiscal year 2011 revenue.

"Our participation at the 63rd PHARMACHINA Fair was a great success. As the market demand for anti-depressants and nerve-regulating treatments continues to grow, our Siberiana Ginseng-based product series generated significant interest at the Fair," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We signed several agreements with new distributors and anticipate these deals will positively contribute to our revenue in fiscal 2011. As an increasing number of consumers seek alternatives to expensive chemical-based anti-depressants, we see significant growth opportunity for our cost-effective Siberian Ginseng products with their well-established efficacy and minimal side effects."


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Md. , June 19, 2013 Synthetic Biologics, ... the prevention and treatment of serious infectious diseases, announced today ... 6 th Annual OneMedForum New York Conference on Thursday, ... New York City . Mr. Riley is scheduled to ... webcast of Synthetic Biologics, presentation can be accessed by logging ...
(Date:6/19/2013)... Bayer CropScience will honor Illinois beekeeper ... Community Leadership Award. The award will be announced at ... Washington, D.C., an event where supporters of pollinator health ... supply. , The Bayer Bee Care Community Leadership ... the honey bee colony to benefit their community. Applicants ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 BioConvergence ... the speaking faculty at 2013’s BioLogistics Summit in ... conference, coordinated by Cold Chain IQ and IQPC, ... This “complexity” is, in part, attributed to current ... , “Implicit within these trends is an increase ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... BAX ) announced today that its Board of ... of the company,s,common stock to be executed upon completion ... less than $700 million of remaining authorization under its,previous ... March,2007. Shares will be repurchased in the open market ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
... siRNA Targeting of, VEGF Expression, Further Strengthening OPKO,s RNAi Intellectual Property ... ... OPKO Health, Inc. (Amex: OPK ),today announced that it has been ... for methods related to the use and,administration of small interfering RNAs (siRNAs) ...
Cached Biology Technology:Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4
(Date:6/19/2013)... new variety of canary seeds bred specifically for human ... ideal for people with celiac disease (CD), scientists have ... of Agricultural and Food Chemistry . , Joyce ... 3 million people in the United States alone have ... wheat, barley, rye and other grains that contain gluten-related ...
(Date:6/19/2013)... A Cornell University study offers further proof that the ... 6 million years ago was profoundly influenced by mutations ... on and off. , The study, published June 9 ... 40-year-old hypothesis that regulation of genes must play an ... between humans and chimps in the proteins produced by ...
(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals ... journal aims to provide a forum for rapid publication ... The journal will be co-edited by six Executive Editors, ...
Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... genetic diversity in crops is traditional practice for agriculture ... develop breeding programs with great care for the security ... numerous risks the world,s food supplies face with the ... essential as an insurance against unforeseeable changes in the ...
... -- A Duke University-led team has brought powerful software ... Working together, computer scientists and biochemists have developed and ... to change the machinery that bacteria use to make ... set of computer rules known as the algorithm "K*" ...
... distinguishes itself as the fastest growing greenhouse gas in ... emissions depends on our ability to measure the increase ... increase. Until the late 1950s when high ... whether the industrial revolution and the associated increase in ...
Cached Biology News:Identifying mega-targets for high-yield plant breeding 2Duke software dramatically speeds enzyme design 2Duke software dramatically speeds enzyme design 3Carbon accounting from atmospheric measurements -- the aircraft perspective 2
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
... BIP-NC H-IPMIK-OH ... PROTECT FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT ... Bax-Inhibiting Peptide, V5 (Cat. No. 196810) that ... suppress Bax-mediated apoptosis (~200 μM). Purity: ...
Biology Products: